1. Scrip
  2. >>Business
  4. >>Emerging Company Profiles

SpyGlass To Boost Ophthalmic Drug Adherence With Intraocular Delivery Platform

After $90m Series C

 
• By Ayisha Sharma

Emerging Company Profile: The US biotech SpyGlass is gearing up for a Phase I/II trial in glaucoma after recently closing a $90m fundraising to help advance its intraocular delivery platform to address poor treatment adherence in chronic eye diseases.  

Emerging Company Profile: SpyGlass Pharma
SpyGlass' Drug-Eluting Pads Are Attached To The Haptics Of The Lens • Source: Shutterstock
Key Takeaways:

  • The $90m raise was led by RA Capital Management and included both old and new investors.

SpyGlass Pharma is using its proprietary intraocular drug-delivery system to develop more convenient treatment options for chronic eye diseases with the help of a $90m series C fundraising round completed earlier this month.

The round was led by RA Capital Management alongside historical investors New Enterprise Associates and Vensana Capital, and also included...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

More from Start-Ups & SMEs